The short version
Sprout Health is a compounded GLP-1 telehealth provider with a specific focus on orally disintegrating tablet (ODT) formulations — tablets that dissolve on or under the tongue rather than being swallowed. Their compounded semaglutide ODT program runs around $199 per month with step-up pricing at higher doses.
Sprout did not receive an FDA warning letter in the February or March 2026 enforcement actions. Combined with a reasonably transparent operation and a specific clinical specialty (the ODT format), this puts Sprout in the middle of our compounded provider rankings — not the cheapest, not the highest-profile, but one of the cleaner regulatory records in the category.
This review focuses on what Sprout does well, what its ODT approach actually means clinically, and how it stacks up against alternatives for different patient situations.
This review contains affiliate links. Compounded medications are not FDA-approved for safety, effectiveness, or quality as finished products.
Why the ODT format matters — and what it doesn't solve
An orally disintegrating tablet dissolves rapidly in the mouth, which can make the medication easier to take for patients who struggle with swallowing conventional tablets or who have specific preferences around dosing experience. The ODT format is legitimately different from a standard swallowed tablet, a sublingual (under-the-tongue) drop, or an injection.
What the ODT format does not change is the fundamental pharmacokinetic challenge of oral semaglutide. Semaglutide is a large peptide molecule. The FDA-approved oral semaglutide product, Rybelsus, achieves systemic absorption through a specific co-formulated absorption enhancer called SNAC (salcaprozate sodium), and even with SNAC the bioavailability is roughly 0.4 to 1 percent. Compounded ODT semaglutide does not generally include SNAC or a functionally equivalent enhancer. The absorption pathway for compounded ODT semaglutide is not well-documented in published human pharmacokinetic literature.
That is not a statement about Sprout specifically — it is a statement about the compounded oral semaglutide category. The clinical question is open, and it applies to every compounded oral format including ODT, sublingual drops, and troches.
Patients choosing a compounded ODT product should understand that they may be receiving a medication whose absorption and effective dosing has not been established at the same level of rigor as the FDA-approved injectable forms. This is a reason to discuss the choice with your clinician and to monitor your response carefully.
Pricing and billing
| Product | Starting price | Notes |
|---|---|---|
| Compounded semaglutide ODT | $199/mo | Introductory; steps up to $249/mo at maintenance doses |
| Compounded tirzepatide | $249/mo | Introductory; steps up to $299/mo at higher doses |
Pricing is cash-pay on a monthly billing cycle. Verify current prices and cancellation terms directly on Sprout's website before enrolling — published prices have shifted in the category multiple times in 2026, and program-specific promos may apply.
Sprout is not the cheapest option in the compounded category. Wellorithm starts at $147 per month for semaglutide. Care Bare Rx bundles programs at similar or lower effective costs. Where Sprout earns its mid-tier pricing is in its specific format focus and its clean regulatory record — Sprout is not trying to be the cost leader, which is itself a signal about what you are paying for.
The clinical model
Sprout operates a standard asynchronous telehealth intake process. A patient completes an online health questionnaire, a licensed clinician reviews the submission, and if the clinician determines that a compounded GLP-1 is appropriate, a prescription is issued and routed to a partner 503A compounding pharmacy. The medication ships directly to the patient.
The ODT specialty gives Sprout a narrower but more defensible clinical positioning than providers that offer every possible formulation. Clinicians prescribing through Sprout are presumably more familiar with the specific nuances of ODT dosing, patient instructions for oral dissolution timing, and monitoring for appropriate systemic absorption.
Ongoing care is available through the Sprout platform, including follow-up consultations as doses titrate up. The quality and frequency of ongoing clinical touchpoints is something worth asking about specifically during intake if continuous clinical support is a priority for you.
Regulatory standing
Sprout was not among the companies that received FDA warning letters in the February 20, 2026 enforcement action or the March 2026 follow-on wave. That alone does not guarantee Sprout's marketing and labeling fully comply with FDA expectations — the FDA reviews a subset of telehealth websites at any given time and has continued active enforcement throughout 2026. But an absence of enforcement action is a meaningful positive signal compared to peers like MEDVi, Strut Health, SkinnyRx, or the 30+ additional companies cited in March.
Sprout's website, as of our review, does not depict compounded drug product labels bearing the Sprout name in a way that could be read as the company claiming to be the compounder — one of the specific violations the FDA cited in other warning letters. Sprout's regulatory disclosures around compounded status appear to be appropriately prominent.
The FDA's 2026 compounded GLP-1 enforcement program has been described by industry attorneys as "ongoing." Companies that did not receive letters in the first two waves may still be subject to future enforcement if their marketing practices change or if the FDA expands its review scope. Current absence of a letter is a positive signal, not a permanent clean bill of health.
Strengths and concerns
Strengths
- Clean regulatory record — no 2026 FDA warning letter
- Specific focus on ODT format (useful for patients with specific preferences)
- Appropriate disclosure of compounded status
- Clinician-supervised prescribing with licensed U.S. pharmacists filling
- Reasonable transparency on program structure and pricing
Concerns
- Compounded ODT absorption is not well-characterized in published pharmacokinetic data
- Pricing is mid-market — not competitive with Wellorithm or Care Bare Rx on starter cost
- Compounded medications are not FDA-approved as finished products
- Limited published data on long-term patient outcomes specific to the ODT format
- Narrower product range than some competitors (ODT focus means fewer other format options)
Alternatives worth considering
Sprout Health — if ODT format specifically matters to you
If you have specific reasons to prefer the orally disintegrating tablet format and you want a provider with a clean regulatory record, Sprout is a credible mid-market option. Compounded medications are not FDA-approved.
Sesame Care — for the FDA-approved oral path
Sesame Care connects you to clinicians who can prescribe Rybelsus, Wegovy pill, or Foundayo — FDA-approved oral GLP-1s with published pharmacokinetic data and established dosing. If insurance covers these, your cost may be lower than compounded anyway.
SHED — if you want oral format flexibility
SHED offers tablet, ODT, and lozenge options from LegitScript-certified compounding pharmacy partners. Better documentation of the specific pharmacy filling each prescription. A stronger overall pick than Sprout if you want compounded with format flexibility.
Bottom line
Sprout Health earns its place in the compounded GLP-1 category by staying in its lane and avoiding the regulatory issues that have hit louder competitors. The ODT specialty is a real clinical differentiator for patients who value that specific format. Pricing is mid-market, which is both a limitation (not the cheapest) and a feature (Sprout is not competing on the race-to-the-bottom dimension that has created regulatory problems elsewhere).
For most new enrollees, we still recommend starting with Sesame Care for the FDA-approved brand-name path or SHED for broader compounded format options. But Sprout is a legitimate alternative for ODT-specific needs.
How does a semaglutide ODT actually work?
The tablet dissolves in the mouth, releasing the active ingredient. Absorption can occur through the oral mucosa (sublingually or buccally) and through the gastrointestinal tract after swallowing the dissolved medication. The proportion absorbed by each route and the total bioavailability for compounded ODT semaglutide are not well-characterized in published peer-reviewed literature.
Is Sprout's ODT the same as Rybelsus?
No. Rybelsus is an FDA-approved oral semaglutide tablet that includes SNAC (salcaprozate sodium) as an absorption enhancer. Compounded ODT formulations generally do not include SNAC. They are structurally and pharmacokinetically different products — though both contain semaglutide as the active ingredient.
Why choose ODT over injection?
Primary reasons patients choose ODT include needle aversion, travel convenience, and preference for daily-dose familiarity. Clinical trade-offs include the pharmacokinetic uncertainty described above and the absence of the established dosing protocols that exist for injectable semaglutide.
Does Sprout work with insurance?
Sprout operates on a cash-pay model. Insurance reimbursement for compounded GLP-1 medications is rare. If your insurance covers FDA-approved brand-name semaglutide products, your out-of-pocket may be lower going that route.